Frede Donskov
@FDonskov
Followers
241
Following
117
Media
16
Statuses
169
Clinical Professor in Oncology, University Hospital of Southern Denmark, Esbjerg, Denmark.
Joined December 2019
Well-written and insightful paper every oncologist and clinician with frontline clinical workload should read - before burnout.
Oncology is a demanding profession, asking a great amount of those practicing in the field. Oncology clinicians can set boundaries while still meeting ethical practice standards. Setting boundaries may ultimately allow clinicians to be more present & engaged while working, have
0
1
4
RT @brian_rini: Updated IO combo table after #ASCO2023 IO/TKI presentations. VEGF tx provides early disease control while Ipi provides dura….
0
98
0
Any suggestions for a training scheme @HowardGurney ?.
We need comprehensive training schemes for trial coordinators and move beyond the current apprentice scheme. Experienced trial coordinators are in short supply and we need to stop poaching each others.
0
0
0
RT @NielsThem: Flere kvitter, når prisen på cigaretter ryger i vejret. Men prisen skal hoppe, så det kan mærkes - ellers har det ingen effe….
www.altinget.dk
Vi ved fra talrige undersøgelser, at færre unge begynder at ryge og flere stopper, hvis prisen på cigaretter sættes op, så det kan mærkes. Derfor bør den nye regering prioritere få store prisstigni...
0
2
0
RT @tompowles1: I thought only astronauts, bond villains and tech billionaires appeared in TIME magazine. Some people are all 3 but David M….
time.com
New medications are helping patients with kidney cancer live longer
0
12
0
RT @milanhoraplzen: Cytoreductive nephrectomy associated with longer OS in patients with #mRCC treated with immune checkpoint inhibitor (IC….
0
45
0
Very excited to see our work on molecular analysis in Clear Cell & Non-Clear Cell Real-World #Renal Cell Carcinoma just published in @actaoncol. Thanks to great collaborative effort w co-authors. @OncoAlert @DrChoueiri @montypal @brian_rini @TSteiniche
0
2
8
RT @MyriamChalabi: About the smile: the standing ovation also meant that people saw what I knew: behind every one of these bars is a patien….
0
250
0
Awesome discussion!.
Hello to those waking up on the west coast! Had a chance to discuss @DrChoueiri's outstanding presentation of #COSMIC313 at #ESMO22 in the presidential session. Here's a quick synopsis. 1st, what an AMAZING mtg this has been for #kidneycancer (slide credit: @ZeynepZengin) (1/10)
0
0
0
RT @DrChoueiri: A waterfall plot or a tidal wave 🌊???? 🤩 😯 . 99% pathologic response with nivo/ipi in dMMR CRC and NO disease recurrences!!….
0
126
0
Great summary @montypal on adjuvant therapy in #renalcellcarcinoma.
Grateful to @TheLancet for allowing us to publish our experience with #adjuvant #atezolizumab (#IMmotion010) simultaneous w the presentation by #AxelBex at #ESMO22. It's interesting to envision how this data impacts current landscape (link below): (1/10)
1
1
3
0
2
0
RT @DrChoueiri: Our 30-month #KYN564 adjuvant RCC trial is published @TheLancetOncol —led by @tompowles1, presented #GU22 @ASCO —Note HR 0.….
0
82
0
RT @navstruck: Our @IMDConline paper outlining #cabozantinib activity post #immunotherapy combination treatment in #kcsm #kidneycancer is o….
www.clinical-genitourinary-cancer.com
MicroAbstractIn advanced kidney cancer, there is limited data to understand the efficacy of cabozantinib after contemporary first line therapy options. In a 346 patient real world database analysis...
0
9
0
Important study published. Leibovich and GRANT validated in ccRCC and non-ccRCC nationwide #kidneycancer cohort. Leibovich outperformed GRANT in predicting recurrence-free survival and should remain .standard approach to risk stratify patients. @oncoalert.
onlinelibrary.wiley.com
Objective To examine the performance of Leibovich score versus GRade, Age, Nodes, and Tumor score in predicting disease recurrence in renal cell carcinoma. Methods In total, 7653 patients diagnose...
Do we have a Litmus test to predict survival in localized kidney cancer?.🔸7653 patients: GRade, Age, Nodes, and Tumor score (GRANT) 🇩🇰.🔸Leibovich score outperformed the GRANT regarding RFS.@FDonskov @OncoAlert @Uroweb @urotoday @NessnAzawi @KidneyCancer .
0
3
11
Stong 5-yr data just published @KidneyCancer.
CheckMate 214.🔸Durable-long-term efficacy with Nivo-IPI.🔸mFU 67.7 months.🔸mOS: 55.7 months (48% @5Y).🔸After 3 years the probability of remaining alive for an additional 2 years ↗️ with NIVO+IPI regardless of IMDC. @JournalCancer @OncoAlert @DrChoueiri .
0
0
4
RT @DrYukselUrun: CheckMate 214.🔸Durable-long-term efficacy with Nivo-IPI.🔸mFU 67.7 months.🔸mOS: 55.7 months (48% @5Y).🔸After 3 years the p….
0
29
0